REV1 Is Implicated in the Development of Carcinogen-Induced Lung Cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The somatic mutation hypothesis of cancer predicts that reducing the frequency of mutations induced by carcinogens will reduce the incidence of cancer. To examine this, we developed an antimutator strategy based on the manipulation of the level of a protein required for mutagenic bypass of DNA damage induced by the ubiquitous carcinogen benzo[a]pyrene. The expression of this protein, REV1, was reduced in mouse cells using a vector encoding a gene-specific targeting ribozyme. In the latter cells, mutagenesis induced by the activated form of benzo[a]pyrene was reduced by >90%. To examine if REV1 transcripts could be lowered in vivo, the plasmid was complexed with polyethyleneimine, a nonviral cationic polymer, and delivered to the lung via aerosol. The endogenous REV1 transcript in the bronchial epithelium as determined by quantitative real-time PCR in laser capture microdissected cells was reduced by 60%. There was a significant decrease in the multiplicity of carcinogen-induced lung tumors from 6.4 to 3.7 tumors per mouse. Additionally, REV1 inhibition completely abolished tumor formation in 27% of the carcinogen-exposed mice. These data support the central role of the translesion synthesis pathway in the development of lung cancer. Further, the selective modulation of members of this pathway presents novel potential targets for cancer prevention. The somatic mutation hypothesis of cancer predicts that the frequency of cancers will also be reduced. (Mol Cancer Res 2009;7(2):247–54)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Specialized DNA Polymerases, Cellular Survival, and the Genesis of Mutations
Friedberg, E. C., Wagner, R., & Radman, M. (2002) · Science · doi:10.1126/science.1070236 · Cited by 443 · cited 1×
“Recently, insights have been gained into the mechanisms used by cells to complete the replication of damaged genomes and the induction of mutations (5-7).”
Background
Cited by
Lange, S. S., Takata, K.-I., & Wood, R. D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2998 · Cited by 615
Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006842 · Cited by 87
“• Rev1 (Rev1 deficient; near-infertile and unstable genome) [24] • Several hepatocarcinomas and occasional lung cancers show high expression of REV1 [25] (http:// www.”
BackgroundTargeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics
Korzhnev, D. M., & Hadden, M. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00596 · Cited by 58
Vanarotti, M., Evison, B. J., Actis, M. L., Inoue, A., McDonald, E. T., Shao, Y., Heath, R. J., & Fujii, N. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.028 · Cited by 17
Metadata
- Authors
- Dumstorf, C. A., Mukhopadhyay, S., Krishnan, E., Haribabu, B., & McGregor, W. G.
- Venue
- Molecular Cancer Research
- Published
- 2009-02-01
- Volume
- 7
- Issue
- 2
- Pages
- 247-254
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2172105250
- Cited by
- 43
- References
- 2
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: REV1 Is Implicated in the Development of Carcinogen-Induced Lung Cancer. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-08-0399
- The paper
- Dumstorf, C. A., Mukhopadhyay, S., Krishnan, E., Haribabu, B., & McGregor, W. G. (2009). REV1 Is Implicated in the Development of Carcinogen-Induced Lung Cancer. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-08-0399
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.